Please login to the form below

Not currently logged in
Email:
Password:

Immune Therapeutics

This page shows the latest Immune Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

development at CytomX Therapeutics. ... Amgen is not the first big biopharma company to be impressed by CytomX’s Probody therapeutics, which are designed to direct immune T cells to cancer cells, while incorporating a masking

Latest news

  • Sanofi and Ablynx sign €2.4bn nanobody deal Sanofi and Ablynx sign €2.4bn nanobody deal

    The partners will focus on developing and commercialising nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases (IMID). ... a world-leader like Sanofi in the development of a new generation of therapeutics for the

  • Dutch companies partner on vaccines

    Pepscan focuses on protein mimicking technology for the generation of immune therapeutics.

  • Potential blood cancer treatment tested

    Potential blood cancer treatment tested. Immune System Therapeutics has launched a clinical trial to test its breakthrough treatment for terminal blood cancers. ... Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its

  • Pfizer to acquire Coley Pharmaceutical

    Coley's portfolio includes a new class of drug candidates called TLR Therapeutics which stimulate or block immune system Toll-like receptors (TLRs). ... advancing TLR Therapeutic candidates that may be capable of directing the immune system to treat a

  • Forging ahead

    Positive results from ongoing phase II trials of Trinam, Ark Therapeutics' novel gene therapy to prevent blood vessels blocking in kidney dialysis patients who have undergone vascular access graft surgery, were ... Shares in biopharmaceutical company

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx. ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1 immune checkpoint mAb.

  • Pharma deals during September 2012 Pharma deals during September 2012

    Baxter International has been granted a licence for commercialisation rights for Estybon (rigosertib) in Europe by Onconova Therapeutics. ... Lebanese company Immunext is developing novel therapeutics that modulate the immune system to treat cancer, and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Scancell appoints Dr Cliff Holloway as CEO Scancell appoints Dr Cliff Holloway as CEO

    Prior to this, he was chief executive officer and managing director of Sienna Cancer Diagnostics, and has held roles for Immune System Therapeutics and Biosceptre International. ... John Chiplin, executive chairman, Scancell, said: “Cliff’s extensive

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Ex J&J VP joins board of Immune. Cameron Durrant also has senior experience at Pharmacia. ... Immune specialises in developing antibodies to treat patients with inflammatory diseases and cancer.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics